Telix Pharmaceuticals (TLX) Stock Statistics & Valuation Metrics

Telix Pharmaceuticals has a market cap or net worth of AUD 4.42B. The enterprise value is AUD 6.39B.

Market Cap

AUD 4.42B

Enterprise Value

AUD 6.39B

Telix Pharmaceuticals has 340,330,380 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

340,330,380

Owned by Insiders

6.32%

Owned by Institutions

6.53%

Telix Pharmaceuticals’s return on equity (ROE) is -0.02 and return on invested capital (ROIC) is 1.86%.

Return on Equity (ROE)

-0.02

Return on Assets (ROA)

-0.01

Return on Invested Capital (ROIC)

1.86%

Return on Capital Employed (ROCE)

0.02

Revenue Per Employee

708.95K

Profits Per Employee

-6,284.325

Employee Count

1,152

Asset Turnover

0.69

Inventory Turnover

10.32

The current PE Ratio of Telix Pharmaceuticals is 102.76. Telix Pharmaceuticals’s PEG ratio is -0.46.

PE Ratio

102.76

PS Ratio

3.77

PB Ratio

6.84

Price to FCF

-57.09

Price to Operating Cash Flow

-249.55

PEG Ratio

-0.46

In the last 12 months, Telix Pharmaceuticals had revenue of 816.72M and earned -7.24M in profits. Earnings per share was -0.02.

Revenue

816.72M

Gross Profit

433.78M

Operating Income

18.05M

Pretax Income

-5.35M

Net Income

-7.24M

EBITDA

40.18M

Earnings Per Share (EPS)

-0.02

In the last 12 months, operating cash flow was -13.35M and capital expenditures -45.11M, giving a free cash flow of -58.47M billion.

Operating Cash Flow

-13.35M

Free Cash Flow

-58.47M

Free Cash Flow per Share

-0.17

Telix Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-1.84%

Earnings Yield

1.03%

Beta

1.10

52-Week Price Change

-15.43%

50-Day Moving Average

15.53

200-Day Moving Average

14.08

Relative Strength Index (RSI)

35.16

Average Volume (3m)

2.16M

Telix Pharmaceuticals upcoming earnings date is Feb 19, 2027, TBA (Not Confirmed).

Last Earnings Date

Aug 19, 2026

Next Earnings Date

Feb 19, 2027

Ex-Dividend Date

―

Telix Pharmaceuticals as a current ratio of 1.43, with Debt / Equity ratio of 112.34%

Current Ratio

1.43

Quick Ratio

1.27

Debt to Market Cap

0.11

Net Debt to EBITDA

8.09

Interest Coverage Ratio

0.48

In the past 12 months, Telix Pharmaceuticals has paid 1.89M in taxes.

Income Tax

1.89M

Effective Tax Rate

-0.35

Telix Pharmaceuticals EV to EBITDA ratio is 115.38, with an EV/FCF ratio of -59.85.

EV to Sales

3.95

EV to EBITDA

115.38

EV to Free Cash Flow

-59.85

EV to Operating Cash Flow

-262.04

Telix Pharmaceuticals has AUD 251.80M in cash and marketable securities with AUD 579.61M in debt, giving a net cash position of -AUD 327.81M billion.

Cash & Marketable Securities

AUD 251.80M

Total Debt

AUD 579.61M

Net Cash

-AUD 327.81M

Net Cash Per Share

-AUD 0.96

Tangible Book Value Per Share

-AUD 0.29

Gross margin is 52.14%, with operating margin of -0.78%, and net profit margin of 3.69%.

Gross Margin

52.14%

Operating Margin

-0.78%

Pretax Margin

3.19%

Net Profit Margin

3.69%

EBITDA Margin

3.43%

EBIT Margin

-0.78%

The average price target for Telix Pharmaceuticals is AUD 24.93, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

AUD 24.93

Price Target Upside

87.15% Upside

Analyst Consensus

Strong Buy

Analyst Count

10

Revenue Growth Forecast

26.66%

EPS Growth Forecast

179.32%

Smart Score

10

AI Score

53